Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data
Carfilzomib and daratumumab are licensed in relapsed/refractory multiple myeloma (RRMM), but no head-to-head trials have been conducted.
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[2020]
|
| In: |
Quality of life research
Year: 2019, Volume: 29, Issue: 1, Pages: 69-79 |
| ISSN: | 1573-2649 |
| DOI: | 10.1007/s11136-019-02307-5 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11136-019-02307-5
|
| Author Notes: | Katja Weisel, Heinz Ludwig, Achim Rieth, Andrea Lebioda, Hartmut Goldschmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694493296 | ||
| 003 | DE-627 | ||
| 005 | 20220818040607.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200414r20202019xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11136-019-02307-5 |2 doi | |
| 035 | |a (DE-627)1694493296 | ||
| 035 | |a (DE-599)KXP1694493296 | ||
| 035 | |a (OCoLC)1341314932 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Weisel, Katja |d 1971- |e VerfasserIn |0 (DE-588)118014935 |0 (DE-627)079191975 |0 (DE-576)291668887 |4 aut | |
| 245 | 1 | 0 | |a Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data |c Katja Weisel, Heinz Ludwig, Achim Rieth, Andrea Lebioda, Hartmut Goldschmidt |
| 264 | 1 | |c [2020] | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 24 September 2019 | ||
| 500 | |a Gesehen am 14.04.2020 | ||
| 520 | |a Carfilzomib and daratumumab are licensed in relapsed/refractory multiple myeloma (RRMM), but no head-to-head trials have been conducted. | ||
| 534 | |c 2019 | ||
| 700 | 1 | |a Ludwig, Heinz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rieth, Achim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lebioda, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Quality of life research |d Cham : Springer Nature Switzerland AG, 1992 |g 29(2020), 1, Seite 69-79 |h Online-Ressource |w (DE-627)320474399 |w (DE-600)2008960-0 |w (DE-576)121191001 |x 1573-2649 |7 nnas |a Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data |
| 773 | 1 | 8 | |g volume:29 |g year:2020 |g number:1 |g pages:69-79 |g extent:11 |a Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s11136-019-02307-5 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200414 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 5 |y j | ||
| 999 | |a KXP-PPN1694493296 |e 3623058491 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"role":"aut","display":"Weisel, Katja","given":"Katja","family":"Weisel"},{"family":"Ludwig","given":"Heinz","display":"Ludwig, Heinz","role":"aut"},{"family":"Rieth","given":"Achim","display":"Rieth, Achim","role":"aut"},{"given":"Andrea","family":"Lebioda","display":"Lebioda, Andrea","role":"aut"},{"role":"aut","display":"Goldschmidt, Hartmut","family":"Goldschmidt","given":"Hartmut"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Published online: 24 September 2019","Gesehen am 14.04.2020"],"id":{"doi":["10.1007/s11136-019-02307-5"],"eki":["1694493296"]},"physDesc":[{"extent":"11 S."}],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"[2020]"}],"name":{"displayForm":["Katja Weisel, Heinz Ludwig, Achim Rieth, Andrea Lebioda, Hartmut Goldschmidt"]},"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"part":{"text":"29(2020), 1, Seite 69-79","year":"2020","issue":"1","pages":"69-79","volume":"29","extent":"11"},"note":["Gesehen am 19.11.07"],"id":{"eki":["320474399"],"zdb":["2008960-0"],"issn":["1573-2649"]},"disp":"Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment dataQuality of life research","origin":[{"publisherPlace":"Cham ; Oxford ; London ; Dordrecht ; Dordrecht","dateIssuedDisp":"1992-","publisher":"Springer Nature Switzerland AG ; Rapid Communications of Oxford ; Rapid Science Publishers ; Kluwer ; Springer","dateIssuedKey":"1992"}],"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.1992 -"],"title":[{"title_sort":"Quality of life research","title":"Quality of life research","subtitle":"an international journal of quality of life aspects of treatment, care and rehabilitation"}],"recId":"320474399"}],"recId":"1694493296","title":[{"title":"Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data","title_sort":"Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data"}]} | ||
| SRT | |a WEISELKATJHEALTHRELA2020 | ||